Jillian B. Thomsen net worth and biography

Jillian Thomsen Biography and Net Worth

Jillian B. Thomsen was appointed Chief Accounting Officer in April 2008. She has over 20 years of financial reporting and accounting experience. In her current role, Ms. Thomsen oversees accounting, financial reporting, planning & analysis, Sarbanes-Oxley compliance, treasury, and tax functions at the company. Previously, she served as Vice President, Finance and Controller of Nektar.

Prior to joining Nektar in 2006, Ms. Thomsen was Deputy Controller of Calpine Corporation from September 2002 to February 2006. From December 1990 to May 2002, Ms. Thomsen performed various roles with Arthur Andersen starting as a staff accountant and concluding as a senior manager.

Ms. Thomsen holds a Masters of Accountancy degree from the University of Denver and a B.A. in Business Economics from Colorado College.

What is Jillian B. Thomsen's net worth?

The estimated net worth of Jillian B. Thomsen is at least $1.00 million as of November 16th, 2022. Ms. Thomsen owns 323,764 shares of Nektar Therapeutics stock worth more than $1,000,431 as of February 5th. This net worth approximation does not reflect any other investments that Ms. Thomsen may own. Learn More about Jillian B. Thomsen's net worth.

How do I contact Jillian B. Thomsen?

The corporate mailing address for Ms. Thomsen and other Nektar Therapeutics executives is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. Nektar Therapeutics can also be reached via phone at (415) 482-5300 and via email at [email protected] Learn More on Jillian B. Thomsen's contact information.

Has Jillian B. Thomsen been buying or selling shares of Nektar Therapeutics?

Jillian B. Thomsen has not been actively trading shares of Nektar Therapeutics during the past quarter. Most recently, Jillian B. Thomsen sold 11,095 shares of the business's stock in a transaction on Wednesday, November 16th. The shares were sold at an average price of $3.57, for a transaction totalling $39,609.15. Following the completion of the sale, the chief financial officer now directly owns 323,764 shares of the company's stock, valued at $1,155,837.48. Learn More on Jillian B. Thomsen's trading history.

Who are Nektar Therapeutics' active insiders?

Nektar Therapeutics' insider roster includes Robert Chess (Director), Myriam Curet (Director), Gil Labrucherie (CFO), John Northcott (SVP), Howard Robin (CEO), Jillian Thomsen (CAO), Mark Wilson (SVP), and Jonathan Zalevsky (Insider). Learn More on Nektar Therapeutics' active insiders.

Are insiders buying or selling shares of Nektar Therapeutics?

During the last year, insiders at the biopharmaceutical company sold shares 20 times. They sold a total of 314,077 shares worth more than $1,549,090.27. The most recent insider tranaction occured on November, 16th when insider Jonathan Zalevsky sold 13,460 shares worth more than $48,052.20. Insiders at Nektar Therapeutics own 3.4% of the company. Learn More about insider trades at Nektar Therapeutics.

Information on this page was last updated on 11/16/2022.

Jillian B. Thomsen Insider Trading History at Nektar Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/16/2022Sell11,095$3.57$39,609.15323,764View SEC Filing Icon  
8/16/2022Sell2,006$4.76$9,548.56334,859View SEC Filing Icon  
5/16/2022Sell5,841$3.95$23,071.95170,427View SEC Filing Icon  
2/16/2022Sell2,363$10.95$25,874.85View SEC Filing Icon  
8/16/2021Sell13,339$13.83$184,478.37View SEC Filing Icon  
5/17/2021Sell13,391$18.30$245,055.30View SEC Filing Icon  
1/28/2021Sell75,000$18.62$1,396,500.00View SEC Filing Icon  
8/17/2020Sell1,367$19.67$26,888.89View SEC Filing Icon  
2/18/2020Sell1,394$22.35$31,155.90View SEC Filing Icon  
2/6/2020Sell37,500$22.78$854,250.00View SEC Filing Icon  
11/18/2019Sell2,713$17.97$48,752.61View SEC Filing Icon  
8/16/2019Sell1,809$18.15$32,833.3592,668View SEC Filing Icon  
5/16/2019Sell1,928$31.37$60,481.36View SEC Filing Icon  
2/19/2019Sell1,808$42.39$76,641.12View SEC Filing Icon  
2/4/2019Sell16,119$42.16$679,577.04View SEC Filing Icon  
11/16/2018Sell4,016$38.25$153,612.00View SEC Filing Icon  
5/16/2018Sell3,576$83.39$298,202.64View SEC Filing Icon  
4/16/2018Sell13,881$101.46$1,408,366.26View SEC Filing Icon  
2/16/2018Sell2,545$82.94$211,082.30View SEC Filing Icon  
8/16/2017Sell2,648$19.32$51,159.36View SEC Filing Icon  
3/20/2017Sell112,500$19.69$2,215,125.00View SEC Filing Icon  
7/11/2016Sell100,000$15.09$1,509,000.00106,809View SEC Filing Icon  
5/17/2016Sell724$13.58$9,831.927,033View SEC Filing Icon  
2/17/2016Sell716$11.92$8,534.725,158View SEC Filing Icon  
2/10/2016Sell15,000$11.49$172,350.003,999View SEC Filing Icon  
1/19/2016Sell15,000$14.12$211,800.003,999View SEC Filing Icon  
12/3/2015Sell15,000$15.87$238,050.003,999View SEC Filing Icon  
11/11/2015Sell15,000$13.52$202,800.003,499View SEC Filing Icon  
10/6/2015Sell15,000$10.99$164,850.003,499View SEC Filing Icon  
9/23/2015Sell10,000$13.04$130,400.003,499View SEC Filing Icon  
12/22/2014Sell5,000$15.56$77,800.00View SEC Filing Icon  
See Full Table

Jillian B. Thomsen Buying and Selling Activity at Nektar Therapeutics

This chart shows Jillian B Thomsen's buying and selling at Nektar Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Nektar Therapeutics Company Overview

Nektar Therapeutics logo
Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.
Read More

Today's Range

Now: $3.09
Low: $2.89
High: $3.15

50 Day Range

MA: $2.55
Low: $2.03
High: $3.10

2 Week Range

Now: $3.09
Low: $1.99
High: $11.59


1,509,001 shs

Average Volume

1,310,673 shs

Market Capitalization

$580.77 million

P/E Ratio


Dividend Yield